| Literature DB >> 29596461 |
Shail M Govani1,2,3, Peter D R Higgins1, Joel H Rubenstein1,2, Ryan W Stidham1, Akbar K Waljee1,4.
Abstract
OBJECTIVES: Patients with inflammatory bowel disease(IBD) are frequently exposed to computed tomography (CT). Each CT exposes patients to radiation that cumulatively could increase the risk of malignancy, particularly in younger patients. We aim to study the effect of age on CT use in IBD patients seen in the Emergency Department (ED) or the hospital.Entities:
Mesh:
Year: 2018 PMID: 29596461 PMCID: PMC5875842 DOI: 10.1371/journal.pone.0195022
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Comparison of CT use among ED visits and hospitalizations for patients with IBD with pharmaceutical coverage.
| No CT (n = 105,782) | CT (n = 38,365) | Test Statistic(DF) | Test Value | p value | |
|---|---|---|---|---|---|
| Age, mean (SD) | 43.7 (18.5) | 43.7 (16.1) | t(144145) | 0.09 | 0.92 |
| Female (%) | 61,171 (57.8) | 21,753 (56.7) | C2(1) | 14.64 | <0.001 |
| Diagnosis | 46,455 (43.9) | 17,360 (45.3) | C2(2) | 564.30 | <0.001 |
| Ulcerative Colitis (%) | 20,852 (19.7) | 5,525 (14.4) | |||
| Indeterminate Colitis (%) | 38,475 (36.4) | 15,480 (40.4) | |||
| Anti-TNF use at time of visit (%) | 5,599 (5.3) | 2,117 (5.5) | C2(1) | 2.82 | 0.09 |
| Narcotic use in previous 90 days (%) | 37,779 (35.7) | 13,612 (35.5) | C2(1) | 0.67 | 0.41 |
| Immunomodulator use (%) | 8,180 (7.7) | 2,833 (7.4) | C2(1) | 4.85 | 0.03 |
| Steroid use in prior 90 days (%) | 12,143 (11.5) | 4,428 (11.5) | C2(1) | 0.10 | 0.74 |
| Length of stay in days, mean (SD) | 4.8 (6.1) | 5.9 (6.9) | t(102968) | -25.16 | <0.001 |
Univariable predictors of CT use during an Inpatient or ED visit with a first or second diagnosis of IBD.
| Predictor | OR | 95%CI | p value |
|---|---|---|---|
| Age | |||
| <18 | 1 | Reference | |
| 18–35 (versus <18) | 2.19 | 2.06–2.33 | <0.001 |
| >35 (versus <18) | 2.11 | 1.99–2.24 | <0.001 |
| Gender (F vs M) | 0.96 | 0.93–0.98 | <0.001 |
| Current anti-TNF Use | 1.05 | 0.99–1.10 | 0.09 |
| Current Immunomodulator Use | 0.95 | 0.91–1.00 | 0.03 |
| Recent Narcotic Use (90 days) | 0.99 | 0.97–1.01 | 0.41 |
| Recent Surgery (Last 30 days) | 1.87 | 1.67–2.09 | <0.001 |
| Steroid Use (Last 90 days) | 1.01 | 0.97–1.04 | 0.74 |
| Crohn's Diagnosis (vs. UC) | 1.41 | 1.36–1.46 | <0.001 |
| Charlson-Deyo (per 1 point) | 0.87 | 0.85–0.88 | <0.001 |
| Age 18–19 compared to 16–17 | 1.73 | 1.55–1.95 | <0.001 |
| Visit Year | 1 | 0.99–1.01 | 0.75 |
Multivariable predictors of CT use during an inpatient or ED visit with a first or second diagnosis of IBD.
| Predictor | OR | 95%CI | p value |
|---|---|---|---|
| Age | |||
| <18 | 1 | Reference | |
| 18–35 (versus <18) | 2.35 | 2.20–2.52 | <0.001 |
| >35 (versus <18) | 2.21 | 2.07–2.36 | <0.001 |
| Gender (F vs M) | 0.94 | 0.92–0.97 | <0.001 |
| Current anti-TNF Use | 1 | 0.94–1.06 | 0.89 |
| Current Immunomodulator Use | 0.95 | 0.90–1.00 | 0.04 |
| Recent Narcotic Use (90 days) | 0.94 | 0.91–0.97 | <0.001 |
| Recent Surgery (Last 30 days) | 2.14 | 1.88–2.43 | <0.001 |
| Steroid Use (Last 90 days) | 1.03 | 0.99–1.08 | 0.15 |
| Crohn's Diagnosis (vs. UC) | 1.59 | 1.53–1.66 | <0.001 |
| Charlson-Deyo (per 1 point) | 0.87 | 0.85–0.88 | <0.001 |
Fig 1CT utilization by age among patients with IBD in the hospital or ED.
Predicted probability of CT use by age demonstrates an abrupt increase at age 18 (vertical red line) for a male with Crohn’s disease (1A) or ulcerative colitis (1B) on no medications and with no recent surgery.